Decision Benefits Patients with Chronic Wounds in Western U.S. and Alaska

Newport News, VA (February 12, 2013) – Beginning February 15, 2013, Medicare recipients in parts of the western United States and Alaska will benefit from Noridian’s decision to cover TheraSkin®, a real skin therapy that effectively treats chronic wounds.

Arizona, Utah, Idaho, Wyoming, North Dakota, South Dakota, Montana, Washington, Oregon, and Alaska are among the states whose residents with diabetic and venous leg ulcers will have access to cost-effective healing, explained Kerry McCarter, CEO of Soluble Systems, LLC, the parent company of TheraSkin®.

“Noridian, a Fiscal Intermediary for the Centers for Medicare and Medicaid Services, is a leading health care insurance system and we applaud their decision to cover this limb and life-saving product, ” McCarter added.

Patients that have particularly benefited from the wound healing capabilities of TheraSkin® are those with diabetes. “Diabetics are likely to develop foot ulcers and venous leg ulcers, which are often extremely difficult to heal,” added McCarter. “When all else fails, these patients are involved in nearly two-thirds of all non-traumatic lower limb amputations each year.”

TheraSkin® clinical results demonstrate the potential to save many patients from these life-threatening lower limb amputations by effectively closing over 60% of previously “non-healing” diabetic and venous ulcers in 12 weeks.

“Soluble Systems appreciates the extensive scientific review conducted by Noridian, which resulted in the decision to provide reimbursement coverage for TheraSkin®,” said Allan Staley, President of Soluble Systems. “We will work tirelessly with the medical institutions and practitioners in the Noridian network to realize the clinical and economic benefits of TheraSkin® for their insured population.”

TheraSkin® is not only clinically effective, but economical, costing 50 – 70% less than competing products, saving patients and payers thousands of dollars per treatment. A potent new weapon in the battle against rising healthcare costs, TheraSkin® has the potential to save patients and the U.S. healthcare system more than $1 billion over the next decade.

TheraSkin® is a biologically active cryo-preserved human skin allograft for non-responsive chronic wounds. Its fully developed extracellular matrix (ECM) and living cells provide an “at-ready” supply of human growth factors, cytokines and collagen to jumpstart wound healing. Like competing bioengineered skin substitutes, TheraSkin® provides necessary growth factors and cytokines to treat chronic wounds; however, it also provides a large quantity of essential human collagens in appropriate ratios to support healing.

For more information on TheraSkin® and Soluble Systems, LLC, visit